76518-57-5

Basic information

• Product Name: 5-HYDROXYMETHYLISOQUINOLINE
• Synonyms: RARECHEM AL BD 1523;ISOQUINOLINE-5-METHANOL;5-HYDROXYMETHYLISOQUINOLINE;5-ISOQUINOLINEMETHANOL;AKOS P-2123556;8-(HYDROXYMETHYL)ISOQUINOLINE;ISOQUINOLIN-8-YLMETHANOL;Isoquinolin-5-ylMethanol
• CAS NO: 76518-57-5
• Molecular Formula: C10H9NO
• Molecular Weight: 159.18
• Mol File: 76518-57-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 352.3 °C at 760 mmHg
• Flash Point: 166.9 °C
• Appearance: /
• Density: 1.218 g/cm³
• Vapor Pressure: 1.44E-05mmHg at 25°C
• Refractive Index: 1.667
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-HYDROXYMETHYLISOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-HYDROXYMETHYLISOQUINOLINE(76518-57-5)
• EPA Substance Registry System: 5-HYDROXYMETHYLISOQUINOLINE(76518-57-5)

Safety Data

• Hazardous Substances Data: 76518-57-5(Hazardous Substances Data)

Usage

General Description

5-Hydroxymethylisoquinoline is a chemical compound that belongs to the isoquinoline family. It is a derivative of isoquinoline and contains a hydroxymethyl group attached to the fifth position of the isoquinoline ring. 5-HYDROXYMETHYLISOQUINOLINE has been studied for its potential pharmacological properties, including its antioxidant and cytoprotective effects. It has also been investigated for its potential use in the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's. Additionally, 5-hydroxymethylisoquinoline has been used as a fluorescent tag in biological and chemical research applications, due to its unique structural and photophysical properties. Overall, this compound has shown promise for various medicinal and research applications due to its unique chemical structure and potential biological effects.

InChI:InChI=1/C10H9NO/c12-7-9-3-1-2-8-4-5-11-6-10(8)9/h1-6,12H,7H2

Upstream product

• 5632-13-3 1-quinolin-4-ylmethanamine 
• 58794-09-5 7-bromoisoquinoline 
• 6737-42-4 1,3-bis-(diphenylphosphino)propane 
• 34784-04-8 5-bromoisoquinoline 
• 16675-59-5 methyl isoquinoline-5-carboxylate 
• 80278-67-7 isoquinoline-5-carboxaldehyde 

Downstream Products

• 158654-74-1 5-(bromomethyl)isoquinoline 
• 586373-76-4 5-(bromomethyl)isoquinoline hydrobromide 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6

The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

Ruthenium-catalyzed chemo-and enantioselective hydrogenation of isoquinoline carbocycles

A chemoselective hydrogenation of isoquinoline carbocycles was achieved by using the catalyst prepared from Ru(methallyl)2(cod) and trans-chelate chiral ligand PhTRAP. The unique chemoselectivity achieved in this hydrogenation could be ascribed to the trans-chelation of the chiral ligand. The procedure for preparing the catalyst strongly affects the reproducibility of the carbocycle hydrogenation. Various 5-, 6-, 7-, and 8-substituted isoquinolines were selectively hydrogenated at their carbocycles to afford 5,6,7,8-tetrahydroisoquinolines as major products in high yields with moderate or good enantioselectivities. Some mechanistic studies suggested that the stereogenic center was created during the initial addition of H2 to the aromatic ring in the hydrogenation of 5-substituted isoquinolines. In other words, the stereochemical control was accompanied by the dearomatization.

SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A)

The invention relates to compounds of the formula wherein R′, R1, through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.